WENDY HEIN

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Pediatrics KANSAS CITY, MO NPI 1386044576

General Payments — all program years on this page

$261,006.60

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 41
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $150,664.61 across 26 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $150,664.6126

By program year

Program yearAmountRecords
2022 $20.471
2023 $110,321.5214
2024 $150,664.6126

Records — PY2024 (26)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086920483 Novartis Pharmaceuticals Corporation $11,145.83 01/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920485 Novartis Pharmaceuticals Corporation $11,145.83 02/29/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920487 Novartis Pharmaceuticals Corporation $11,145.83 03/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920489 Novartis Pharmaceuticals Corporation $11,475.00 07/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920491 Novartis Pharmaceuticals Corporation $35.00 05/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920493 Novartis Pharmaceuticals Corporation $350.00 05/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920495 Novartis Pharmaceuticals Corporation $1,718.95 05/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920497 Novartis Pharmaceuticals Corporation $2,190.40 05/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920499 Novartis Pharmaceuticals Corporation $11,145.83 04/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920501 Novartis Pharmaceuticals Corporation $11,145.83 05/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920503 Novartis Pharmaceuticals Corporation $10,402.78 06/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920505 Novartis Pharmaceuticals Corporation $11,475.00 08/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920507 Novartis Pharmaceuticals Corporation $750.00 08/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920509 Novartis Pharmaceuticals Corporation $628.09 08/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920511 Novartis Pharmaceuticals Corporation $2,197.80 09/30/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920513 Novartis Pharmaceuticals Corporation $11,475.00 09/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920515 Novartis Pharmaceuticals Corporation $750.00 09/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920517 Novartis Pharmaceuticals Corporation $750.00 10/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920519 Novartis Pharmaceuticals Corporation $1,585.71 10/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920521 Novartis Pharmaceuticals Corporation $11,475.00 10/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920523 Novartis Pharmaceuticals Corporation $750.00 11/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920525 Novartis Pharmaceuticals Corporation $2,113.59 11/30/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920527 Novartis Pharmaceuticals Corporation $11,475.00 11/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1086920529 Novartis Pharmaceuticals Corporation $750.00 12/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086920531 Novartis Pharmaceuticals Corporation $1,113.14 12/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086920533 Novartis Pharmaceuticals Corporation $11,475.00 12/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.